Skip to main content

Table 2 Resistance of RFP, INH and MDR under different factors by sex

From: Regional distribution of Mycobacterium tuberculosis infection and resistance to rifampicin and isoniazid as determined by high-resolution melt analysis

 

Sex

p

 

Males n (%)

Females n (%)

INH-Resistant (%)

445(20.5)

124(16.1)

0.009

RFP-Resistant (%)

345(15.9)

92(12.0)

0.009

MDR-TB (%)

280(12.9)

78(10.2)

0.047

New patients

   

 INH-Resistant (%)

396(20.3)

90(14.5)

< 0.001

 RFP-Resistant (%)

299(15.3)

62(10.0)

< 0.001

 MDR-TB (%)

243(12.4)

51(8.2)

0.004

Previously treated

   

 INH-Resistant (%)

49(22.4)

34(24.0)

0.838

 RFP-Resistant (%)

46(21.0)

30(20.5)

0.916

 MDR-TB (%)

37(16.9)

27(18.5)

0.694

Smear+ (%)

   

 INH-Resistant (%)

277(21.8)

62(15.8)

0.010

 RFP-Resistant (%)

226(17.8)

46(11.7)

0.005

 MDR-TB (%)

180(14.2)

36(9.2)

0.011

Smear- (%)

   

 INH-Resistant (%)

139(18.5)

54(17.2)

0.619

 RFP-Resistant (%)

94(12.5)

38(12.1)

0.875

 MDR-TB (%)

78(10.4)

35(11.1)

0.708

Smear unknow (%)

   

 INH-Resistant (%)

29(19.5)

8(12.9)

0.254

 RFP-Resistant (%)

25(16.8)

8(12.9)

0.480

 MDR-TB (%)

22(14.8)

7(11.3)

0.504

Urban

   

 INH-Resistant (%)

197(24.8)

53(18.7)

0.036

 RFP-Resistant (%)

162(20.4)

42(14.8)

0.039

 MDR-TB (%)

134(16.9)

33(11.6)

0.036

Rural

   

 INH-Resistant (%)

248(18.0)

71(14.7)

0.095

 RFP-Resistant (%)

183(13.3)

50(10.3)

0.012

 MDR-TB (%)

146(10.6)

45(9.3)

0.418

HRM-positive results of Test Year

   

 2019

651(24.6)

215(21.1)

0.027

 2020

679(16.5)

237(12.8)

< 0.001

 2021

843(15.9)

316(12.2)

< 0.001